Evidence map›Paper›PMID 26410809›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2015

Polymeric drugs: Advances in the development of pharmacologically active polymers.

Jing Li, Fei Yu, Yi Chen, David Oupický

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Dendrimers-based Hydrogels and Nanogels for Drug Delivery.Current pharmaceutical biotechnology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Nanotechnology for colorectal cancer detection and treatment.World journal of gastroenterology · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Polymeric Materials as Potential Inhibitors Against SARS-CoV-2.Journal of polymers and the environment · 2022
    Review
  18. Review
  19. Drug delivery carriers with therapeutic functions.Advanced drug delivery reviews · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jing LiCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Fei YuCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Yi ChenCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Department of Chemistry, University of Nebraska Lincoln, Lincoln, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China. Electronic address: david.oupicky@unmc.edu.
University of Nebraska Medical Center · USUniversity of Nebraska–Lincoln · US

Funding

Multilayered redox-responsive nanoparticles for delivery of drug-siRNA combinatioR01EB015216 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2014 to 2017
$1.3M
Nanoparticles based on histone deacetylase inhibitors for combination treatmentsR21EB019175 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2015 to 2016
$430k
Dual-function nanoparticles for oral treatment of inflammatory bowel diseaseR21EB020308 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2015 to 2016
$428k
Drug-based polycations for combination drug-gene deliveryR21EB014570 · NIBIB · WAYNE STATE UNIVERSITY · PI OUPICKY, DAVID · 2012 to 2013
$410k
NIBIB NIH HHS R01 EB015216NIBIB NIH HHS R21 EB014570NIBIB NIH HHS R21 EB019175NIBIB NIH HHS R21 EB020308
6 · The paper itself

Abstract

Synthetic polymers play a critical role in pharmaceutical discovery and development. Current research and applications of pharmaceutical polymers are mainly focused on their functions as excipients and inert carriers of other pharmacologically active agents. This review article surveys recent advances in alternative pharmaceutical use of polymers as pharmacologically active agents known as polymeric drugs. Emphasis is placed on the benefits of polymeric drugs that are associated with their macromolecular character and their ability to explore biologically relevant multivalency processes. We discuss the main therapeutic uses of polymeric drugs as sequestrants, antimicrobials, antivirals, and anticancer and anti-inflammatory agents.

Indexed as

AnimalsAnti-Bacterial AgentsAntiviral AgentsHumansNeoplasmsPolymersAnti-Bacterial AgentsAntiviral AgentsPolymersAntimicrobialsAntiviralsCancerDendrimersDrug deliveryGene deliveryMultivalencyPolymeric drugsPolymeric sequestrantsPolymer therapeuticsSiRNA deliveryTumor delivery

Identifiers

PMID26410809
PMCPMC4656093
OpenAlexW1816604397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.